LifeVantage Corporation filings document formal disclosures for a Nasdaq-listed health and wellness company that sells nutrigenomic supplements, skin and hair care products, energy drink mixes, and pet supplements through an independent Consultant model. Recent Form 8-K reports furnish quarterly operating results and describe revenue by region, earnings measures, capital allocation, and material corporate events.
Proxy and meeting filings cover board elections, advisory executive compensation votes, auditor ratification, incentive-plan matters, and final stockholder voting results. Other current reports address executive departures, officer appointments, board changes, transition agreements, and compensatory arrangements, alongside exhibit-based press releases tied to financial results and governance actions.
Lifevantage Corp (LFVN) reported that Chief Sales Officer Kristen Cunningham executed several transactions in the company’s common stock. On September 14, 2026, she sold 8,901 shares at a weighted average price of $6.18 per share, with individual trade prices ranging from $6.15 to $6.26. She also sold 100 shares at $6.41 on September 11, 2026, and on September 10, 2026, 2,254 shares were delivered or withheld for payment of exercise price or tax liability at $6.37 per share. No Rule 10b5-1 trading plan is reported for these transactions.
LifeVantage Corp (LFVN) reported materially weaker results for the fourth quarter and full fiscal year ended June 30, 2026. Q4 revenue was $42.4 million, down 23.1% year over year, with Americas revenue down 24.8% and Asia/Pacific & Europe down 16.9%. Q4 net income was $1.3 million or $0.10 per diluted share, versus $0.15 a year ago, and adjusted EBITDA fell to $2.7 million from $4.8 million.
For fiscal 2026, revenue was $182.6 million, a 20.1% decline from 2025, driven by lower MindBody GLP-1 System sales, fewer orders, and smaller average order size, partially offset by the LoveBiome acquisition. Net income dropped to $5.1 million ($0.40 per diluted share) from $9.8 million ($0.75), and adjusted EBITDA decreased to $13.7 million from $22.1 million. Gross margin remained high at 77.6%, and the company ended the year with $14.9 million in cash, no debt, and $10.2 million of operating cash flow. Active accounts declined 21.2% to 104,000. LifeVantage repurchased about 336,000 shares for $2.0 million and is not issuing fiscal 2027 guidance following a CEO transition.
LifeVantage Corporation (LFVN) reports on its fiscal year ended June 30, 2026, highlighting a direct-selling nutrigenomics business focused on dietary supplements, skin and hair care, energy drinks, gut health, and pet products. The company operates primarily through independent consultants across the Americas, Asia/Pacific, and Europe.
Net revenue was $182.6 million, down from $228.5 million in 2025, with the Americas contributing 78.2% and Asia/Pacific & Europe 21.8%. U.S. sales represented about 74% of revenue and Japan about 13%. LFVN closed Hong Kong and Singapore on May 31, 2026 and expanded into Iceland and Portugal.
The company launched multiple new products and systems, including the patent-pending P84 System for gut health and the MindBody GLP-1 System for weight management, and integrated assets acquired from LoveBiome. It continued rolling out its “Evolve” compensation plan and expanded its Rewards Circle loyalty program. As of August 26, 2026, 12,527,348 common shares were outstanding; non-affiliate market value was approximately $63.7 million as of December 31, 2025. The filing outlines extensive regulatory, operational, technology, and direct-selling risks.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 669,418 shares of Lifevantage Corp common stock, representing 5.31% of the outstanding class. The securities relate to Lifevantage Corp’s common stock with a par value of $0.0001 per share.
Renaissance Technologies LLC holds sole voting power and sole dispositive power over all 669,418 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from any sale of these Lifevantage shares.
Moorehead Terrence reported acquisition or exercise transactions in this Form 4 filing.
Lifevantage Corp granted President and CEO Terrence Moorehead equity awards on August 6, 2026. He received 308,642 shares of common stock as a stock unit award that vests in three equal installments on August 6 of 2027, 2028, and 2029, subject to continued service. He was also granted 540,123 Performance Restricted Stock Units (PRSUs), each representing one share of common stock. These PRSUs vest only if specified financial performance targets are achieved over a three-year period from August 6, 2026 to August 6, 2029, with 10% vesting at each achievement date and an additional 10% vesting on the first anniversary of each such achievement date, contingent on continued service.
Lifevantage Corp filed an initial statement of beneficial ownership for Terrence Moorehead, who is identified as a director and as the company’s President and CEO. The filing reports no specific shareholdings or transactions at this time and includes an exhibit titled Power of Attorney.
LifeVantage Corporation’s Board approved the 2026 New Employee Long-Term Incentive Plan on July 31, 2026. The plan is substantially similar to the 2017 Long-Term Incentive Plan, except that incentive stock options cannot be issued and awards may only be granted to recipients eligible under Nasdaq rules.
The plan was adopted by the Board without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4) as an inducement plan. The Board initially reserved 1,500,000 shares of common stock for awards, which may only be granted to qualifying new hires or rehires where the grant is an inducement material to entering into employment.
BlackRock, Inc. filed an amended Schedule 13G reporting passive ownership of common stock of LifeVantage Corp (LFVN). BlackRock and its reporting business units beneficially own 229,432 LifeVantage common shares, representing 1.8% of the outstanding class.
BlackRock reports sole voting power and sole dispositive power over all 229,432 shares, with no shared voting or dispositive power. Various underlying clients may have rights to dividends or sale proceeds, but no single person has an interest in more than five percent of LifeVantage’s outstanding common shares.
Lifevantage Corp Chief Financial Officer Aure Carl reported a tax-related share disposition on Common Stock. A total of 1,361 shares were used to satisfy tax obligations at a reference price of $6.25 per share. After this tax-withholding disposition, Carl directly holds 155,554 shares of Lifevantage common stock.
Lifevantage Corp Chief Sales Officer Kristen Cunningham reported a tax-withholding disposition of company stock tied to equity compensation. On the reported date, 1,717 shares of common stock were withheld at a price of $6.25 per share to cover tax obligations. After this transaction, she directly holds 131,417 shares of Lifevantage common stock, so her overall ownership remains substantial and the event appears routine and compensation-related rather than an open-market trade.